Soumerai SB, Ross-Degnan D. Inadequate prescription-drug coverage for Medicare enrollees—a
call to action. N Engl J Med.1999;340:722-728.
Adams AS, Soumerai SB, Ross-Degnan D. The case for a Medicare drug coverage benefit: a critical review of
the empirical evidence. Annu Rev Public Health.2001;22:49-61.
Prescription drug coverage for Medicare beneficiaries: a side-by-side
comparison of selected proposals. In: Health Policy Alternatives I. Washington,
DC: Henry J. Kaiser Family Foundation; 2000.
McClellan M, Spatz ID, Carney S. Designing a Medicare prescription drug benefit: issues, obstacles,
and opportunities. Health Aff (Millwood).2000;19:26-41.
Pear R, Toner R. Despite high hopes, drug plan may be disappointing to elderly. New York Times.July 22, 2001;sect A:1.
Stuart B, Zacker C. Who bears the burden of Medicaid drug copayment policies? Health Aff (Millwood).1999;18:201-212.
Jensen GA, Morrisey MA. Employer-sponsored postretirement health benefits: not your mother's
Medigap plan. Gerontologist.1992;32:693-703.
Gross D. State Pharmacy Assistance Programs. Washington, DC: AARP Public Policy Institute; 1999.
Poisal JA, Chulis GS. Medicare beneficiaries and drug coverage. Health Aff (Millwood).2000;19:248-256.
Poisal JA, Murray L. Growing differences between Medicare beneficiaries with and without
drug coverage. Health Aff (Millwood).2001;20:74-85.
Davis M, Poisal J, Chulis G, Zarabozo C, Cooper B. Prescription drug coverage, utilization, and spending among Medicare
beneficiaries. Health Aff (Millwood).1999;18:231-243.
Adams AS, Soumerai SB, Ross-Degnan D. Use of antihypertensive drugs by Medicare enrollees: does type of drug
coverage matter? Health Aff (Millwood).2001;20:276-286.
Blustein J. Drug coverage and drug purchases by Medicare beneficiaries with hypertension. Health Aff (Millwood).2000;19:219-230.
Long SH. Prescription drugs and the elderly: issues and options. Health Aff (Millwood).1994;13:157-174.
Stuart B, Grana J. Ability to pay and the decision to medicate. Med Care.1998;36:202-211.
Hodgson TA, Cohen AJ. Medical care expenditures for selected circulatory diseases: opportunities
for reducing national health expenditures. Med Care.1999;37:994-1012.
Wang TJ, Stafford RS. National patterns and predictors of β-blocker use in patients
with coronary artery disease. Arch Intern Med.1998;158:1901-1906.
Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary
artery disease. J Gen Intern Med.1999;14:711-717.
Seddon M, Ayanian JZ, Landrum MB.
et al. Quality of ambulatory care after myocardial infarction among Medicare
patients by type of insurance and region. Am J Med.2001;111:24-32.
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID)
Study Group. Prevention of cardiovascular events and death with pravastatin in patients
with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med.1998;339:1349-1357.
Pedersen TR, Wilhelmsen L, Faergeman O.
et al. Follow-up study of patients randomized in the Scandinavian simvastatin
survival study (4S) of cholesterol lowering. Am J Cardiol.2000;86:257-262.
Hjalmarson A. International β-blocker review in acute and postmyocardial infarction. Am J Cardiol.1988;61:26B-29B.
Viscoli CM, Horwitz RI, Singer BH. β-blockers after myocardial infarction: influence of first-year
clinical course on long-term effectiveness. Ann Intern Med.1993;118:99-105.
Bowlin SJ, Morrill BD, Nafziger AN, Jenkins PL, Lewis C, Pearson TA. Validity of cardiovascular disease risk factors assessed by telephone
survey: the Behavioral Risk Factor Survey. J Clin Epidemiol.1993;46:561-571.
Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitor therapy in older patients with myocardial infarction. Ann Intern Med.2000;132:780-787.
Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic
antagonists after acute myocardial infarction. N Engl J Med.1988;319:152-157.
Phillips KA, Shlipak MG, Coxson P.
et al. Health and economic benefits of increased β-blocker use following
myocardial infarction. JAMA.2000;284:2748-2754.
Prosser LA, Stinnett AA, Goldman PA.
et al. Cost-effectiveness of cholesterol-lowering therapies according to selected
patient characteristics. Ann Intern Med.2000;132:769-779.
Book Drug Topics Red. 101st ed. Montvale, NJ: Medical Economics Co Inc; 1997.
Adler GS. A profile of the Medicare Current Beneficiary Survey. Health Care Financ Rev.1994;15:153-163.
Alecxih L, Corea J, Gross D, Caplan C, Brangan N, Gibson MJ. In reply to: Methodological biases in estimating the burden of out-of-pocket
expenses. Health Serv Res.2001;35:1365-1370.
Rice T, McCall N, Boismier JM. The effectiveness of consumer choice in the Medicare supplemental health
insurance market. Health Serv Res.1991;26:223-246.
Avorn J, Monette J, Lacour A.
et al. Persistence of use of lipid-lowering medications: a cross-national
Ettner SL. Adverse selection and the purchase of Medigap insurance by the elderly. J Health Econ.1997;16:543-562.
Research Triangle Institute. Professional Software for Survey Data Analysis (SUDAAN)
User's Manual, Release 7.5. Research Triangle Park, NC: Research Triangle Institute; 1997.
Hosmer DL. Applied Logistic Regression. New York, NY: John Wiley & Sons Inc; 1989:82-134.
Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of β-blockers in elderly survivors
of acute myocardial infarction. JAMA.1997;277:115-121.
Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary
heart disease. Circulation.1995;92:1326-1331.
Johnson RE, Goodman MJ, Hornbrook MC, Eldredge MB. The impact of increasing patient prescription drug cost sharing on
therapeutic classes of drugs received and on the health status of elderly
HMO members. Health Serv Res.1997;32:103-122.
Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid: effects
on therapy, cost, and equity. N Engl J Med.1987;317:550-556.
Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin T, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and
nursing homes. N Engl J Med.1991;325:1072-1077.
Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use
of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med.1994;331:650-655.
Tamblyn R, Laprise R, Hanley JA.
et al. Adverse events associated with prescription drug cost-sharing among
poor and elderly persons. JAMA.2001;285:421-429.
Davidson BN, Sofaer S, Gertler P. Consumer information and biased selection in the demand for coverage
supplementing Medicare. Soc Sci Med.1992;34:1023-1034.
Wolfe JR, Goddeeris JH. Adverse selection, moral hazard, and wealth effects in the Medigap
insurance market. J Health Econ.1991;10:433-459.
Vistnes JP, Banthin JS. The demand for Medicare supplemental insurance benefits: the role of
attitudes toward medical care and risk. Inquiry.1997;34:311-324.
Harnick DJ, Cohen JL, Schechter CB, Fuster V, Smith DA. Effects of practice setting on quality of lipid-lowering management
in patients with coronary artery disease. Am J Cardiol.1998;81:1416-1420.
Miller M, Byington R, Hunninghake D, Pitt B, Furberg CD.for the Prospective Randomized Evaluation of the Vascular Effects of
Norvasc Trial (PREVENT) Investigators. Sex bias and underutilization of lipid-lowering therapy in patients
with coronary artery disease at academic medical centers in the United States
and Canada. Arch Intern Med.2000;160:343-347.
Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S.for the HERS Research Group. Adherence to National Cholesterol Education Program: treatment goals
in postmenopausal women with heart disease: the Heart and Estrogen/Progestin
Replacement Study (HERS). JAMA.1997;277:1281-1286.
Sempos CT, Cleeman JI, Carroll MD.
et al. Prevalence of high blood cholesterol among US adults: an update based
on guidelines from the second report of the National Cholesterol Education
Program Adult Treatment Panel. JAMA.1993;269:3009-3014.
Jackevicius CA, Tu JV, Leiter L, Anderson GM. Impact of the results of the landmark 4S Lipid Lowering Trial on prescribing
habits for an elderly population. J Am Coll Cardiol.2000;35(suppl 1):314A.
Randomised trial of cholesterol lowering in 4444 patients with coronary
heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet.1994;344:1383-1389.
Sacks FM, Pfeffer MA, Moye LA.
et al. The effect of pravastatin on coronary events after myocardial infarction
in patients with average cholesterol levels. N Engl J Med.1996;335:1001-1009.
Berk ML, Schur CL, Mohr P. Using survey data to estimate prescription drug costs. Health Aff (Millwood).1990;9:146-156.
Moeller JF, Mathiowetz NA. Correcting errors in prescription drug reporting: a critique. Health Aff (Millwood).1991;10:210-214.